Refine by
Stem Cell Transplant Articles & Analysis: Older
41 news found
Groups listed by CDC as being at elevated risk of developing invasive mold infections include those who: · Have had a transplant, especially hematopoietic stem cell transplants · Have cancer, especially hematologic cancers like leukemia and lymphoma · Are undergoing cancer treatment ...
Groups listed by the CDC as being at elevated risk of developing invasive mold infections include those who: · Have had a transplant, especially hematopoietic stem cell transplants · Have cancer, especially hematologic cancers like leukemia and lymphoma · Are undergoing cancer ...
Therefore, HLA typing is essential to the research of immune-related diseases, the screening of vaccine and drug target populations, the study of ethnic evolution, tissue, organ transplantations, etc. The HLA gene products can be expressed on different cell surfaces and play critical roles in antigen presentation and immune signaling. It is closely related to ...
” Business Highlights & Clinical Updates Provided update from the ongoing Phase 1 clinical trial of INB-100 in patients with leukemia who are undergoing haploidentical stem cell transplantation. All three high-risk AML patients from the first cohort continued to demonstrate durable morphologic CR and remained progression-free and ...
(Nasdaq: INAB), a clinical-stage biopharmaceutical company discovering and developing innovative gamma-delta T cell therapies that utilize its DeltEx platform, today announced positive early data from the ongoing Phase 1 trial evaluating INB-100, an allogeneic gamma-delta T cell therapy, in patients with high-risk acute myeloid leukemia (AML) undergoing ...
RESKUE is the first-in-human clinical trial where patients with Krabbe disease are administered FBX-101, a systemic adeno-associated virus (AAV) gene replacement strategy, after full myeloablation and hematopoietic stem cell transplantation (HSCT) infusion. Krabbe is a rare, genetic, neurodegenerative leukodystrophy affecting the central nervous ...
The USA boasts better cancer survival rates than most other developed countries. This was made possible due to a number of factors. In America, much attention is paid to medical equipment. Local oncology centers are equipped with the latest technology, actively use innovative technologies and new medicines. In addition, oncology in the United States involves extensive screening and more ...
“The Dunbar CAR T-Cell Program has a superb facility designed specifically to advance the development of promising T-cell therapies. ...
The parties’ aim is to firstly strengthen Grafalon’s position in the field of transplantation medicine in China, in which it is already approved for marketing and included in China’s National Reimbursement Drug List. Further, the Agreement entails clinical development to expand Grafalon’s regulatory approval in China to the prevention of Graft versus Host ...
While early transplant can help patients, they inevitably develop motor disease. FBX-101, a systemic AAV therapy administered after hematopoietic stem cell transplantation, was well tolerated in the first patient and the initial clinical data support normal brain development during this period of rapid myelination, and normal ...
This program is an allogeneic, or donor-derived, gamma-delta T cell therapeutic candidate in development for patients with high-risk leukemias undergoing haploidentical hematopoietic stem cell transplant (HSCT). ...
The patent broadens the Company’s intellectual property coverage of genetically engineered innate immune cells beyond gamma-delta T cells to include NK cells. Like gamma-delta T cells, NK cells respond directly to cellular stress and have shown promise in cellular therapy clinical trials. ...
“My career has always been directed toward advancing novel disruptive therapies. Gamma-delta T cells are the prototype of ‘unconventional’ T cells, having both innate and adaptive immune properties. ...
Fehniger, MD, PhD, Professor of Medicine, Washington University School of Medicine, an internationally recognized leader in natural killer (NK) cell immunotherapy, stem cell transplantation and lymphomas Prof. Dr. ...
Moreover, AFM28 also depleted leukemic cells from patient bone marrow without destroying CD34-positive/CD123-negative cells, suggesting sparing of hematopoietic stem and progenitor cells. ...
Yago Nieto, M.D., Ph.D., Professor of Stem Cell Transplantation and Cellular Therapy at MD Anderson, presented follow-up data to the investigator sponsored trial (IST) (AFM13-104) investigating the combination of AFM13 pre-complexed with cord blood-derived natural killer cells followed by AFM13 monotherapy in relapsed/refractory ...
This suggests SER-109 has a side effect profile comparable to placebo and may significantly reduce rCDI rates, which disproportionately affect cancer patients. Phase 1b Study of SER-155 in Stem Cell Transplant Hematopoietic stem cell transplant (HSCT) is frequently used to treat lymphoma, ...
(Nasdaq: MCRB) is a leading microbiome therapeutics company developing a novel class of multifunctional bacterial consortia that are designed to functionally interact with host cells and tissues to treat disease. Seres’ SER-109 program achieved the first-ever positive pivotal clinical results for a targeted microbiome drug candidate and has obtained Breakthrough Therapy and ...
At one year, the overall survival without allogeneic hematopoietic stem cell transplantation across the cohort is 100% based on the Kaplan-Meier estimate. ...
(Nasdaq: MCRB), a leading microbiome therapeutics company, will present preclinical findings tomorrow at the European Bone Marrow Transplantation (EBMT) Annual Meeting that suggest SER-155 works by targeting the host immune response, potentially allowing patients undergoing hematopoietic stem cell transplantation (HSCT) to avoid ...